PMID- 35529791 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2218-6751 (Print) IS - 2226-4477 (Electronic) IS - 2218-6751 (Linking) VI - 11 IP - 4 DP - 2022 Apr TI - The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study. PG - 647-655 LID - 10.21037/tlcr-22-252 [doi] AB - BACKGROUND: In early and locally advanced stage non-small-cell lung cancer (NSCLC), surgery is the cornerstone of curative-intent treatments. And the addition of neoadjuvant or adjuvant chemotherapy can prolong overall survival (OS), albumin-bound paclitaxel plus carboplatin (ab-PC) as neoadjuvant therapy (NAT) has showed favorable effect for resectable lung squamous cell carcinoma (LSCC) with IIIA. However, to date, no study has investigated the efficacy of ab-PC as neoadjuvant chemotherapy in potentially resectable LSCC with IIIA-IIIB. This study aimed to evaluate the efficacy and safety of the regimen in potentially resectable LSCC. METHODS: Enrolled patients with stage IIIA and IIIB potentially resectable LSCC treated with neoadjuvant albumin-bound paclitaxel (nab-P; 100 mg/m(2), days 1, 8, and 15) and carboplatin (6 mg/mL/min, day 1) for two 21-day cycles at the Hunan Cancer Hospital between December 2017 and December 2019. The primary endpoint was the surgery conversion rate (SCR). Secondary endpoints included objective response rate (ORR), margin-free (R0) resection, major pathological response (mPR), and safety. RESULTS: In total, 49 patients were included in the study, with an overall response rate (ORR) of 67% (33/49). The SCR was 67% (33/49). Only 31 patients underwent surgery eventually, and R0 resection was achieved in 30 patients. Further, 4 (13%) and 11 (35%) of the 31 patients had a pathological complete response (pCR) and mPR, respectively. In total, 23 patients experienced treatment-related adverse events (TRAEs). The most common TRAE was liver disfunction (9 patients, 18%). Only 1 patient (2%) experienced a grade >/=3 TRAE of leukopenia. There were no treatment-related deaths or treatment discontinuations. CONCLUSIONS: In this study, we found a high SCR (67%) and mPR (35%) after ab-PC treatment for stage IIIA and IIIB potentially resectable LSCC. ab-PC maybe considered a neoadjuvant chemotherapy option for potentially resectable LSCC patients. CI - 2022 Translational Lung Cancer Research. All rights reserved. FAU - Jiang, Wenjuan AU - Jiang W AD - Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China. AD - Department of Oncology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, China. AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Zhou, Yuling AU - Zhou Y AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Zeng, Liang AU - Zeng L AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Xiong, Yi AU - Xiong Y AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Liu, Li AU - Liu L AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Zhou, Chunhua AU - Zhou C AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Yang, Haiyan AU - Yang H AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Guo, Hui AU - Guo H AD - Department of Pathology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Minervini, Fabrizio AU - Minervini F AD - Department of Thoracic Surgery, Cantonal Hospital Lucerne, Lucerne, Switzerland. FAU - Bongiolatti, Stefano AU - Bongiolatti S AD - Thoracic Surgery Unit, Careggi University Hospital, Florence, Italy. FAU - Yang, Nong AU - Yang N AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Zhang, Yongchang AU - Zhang Y AD - Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. FAU - Tao, Min AU - Tao M AD - Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China. AD - Department of Oncology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, China. LA - eng PT - Journal Article PL - China TA - Transl Lung Cancer Res JT - Translational lung cancer research JID - 101646875 PMC - PMC9073738 OTO - NOTNLM OT - Potentially resectable lung squamous cell carcinoma (potentially resectable LSCC) OT - carboplatin OT - neoadjuvant albumin-bound paclitaxel (nab-P) OT - neoadjuvant chemotherapy OT - pathological response COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-252/coif). The authors have no conflicts of interest to declare. EDAT- 2022/05/10 06:00 MHDA- 2022/05/10 06:01 PMCR- 2022/04/01 CRDT- 2022/05/09 04:15 PHST- 2022/01/17 00:00 [received] PHST- 2022/04/20 00:00 [accepted] PHST- 2022/05/09 04:15 [entrez] PHST- 2022/05/10 06:00 [pubmed] PHST- 2022/05/10 06:01 [medline] PHST- 2022/04/01 00:00 [pmc-release] AID - tlcr-11-04-647 [pii] AID - 10.21037/tlcr-22-252 [doi] PST - ppublish SO - Transl Lung Cancer Res. 2022 Apr;11(4):647-655. doi: 10.21037/tlcr-22-252.